Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.86 |
| ▸ | CES2 | O00748 | 1/20 | 0.86 |
| ▸ | CA1 | P00915 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246747 | 0.93 | CES2 (0.81) | CES1CES2CA1CA2BCHE | |
| SCHEMBL223704 | 0.93 | CES1 (1.00) | CES1CES2CA1CA2BCHE | |
| Water SCHEMBL9045475 | 0.91 | CES1 (0.96) | CES1CES2CA1CA2BCHE | |
| SCHEMBL11588711 | 0.91 | CES1 (0.96) | CES1CES2CA1CA2BCHE | |
| SCHEMBL11588705 | 0.91 | CES1 (0.96) | CES1CES2CA1CA2BCHE | |
| Bromide SCHEMBL11420868 | 0.91 | CES1 (0.96) | CES1CES2CA1CA2BCHE | |
| SCHEMBL233887 | 0.86 | CES2 (0.86) | CES1CES2CA1CA2BCHE | |
| Pyrophosphoric Acid SCHEMBL29033361 | 0.86 | CES1 (0.86) | CES1CES2CA1CA2BCHE | |
| SCHEMBL609222 | 0.84 | CES1 (0.83) | CES1CES2CA1CA2BCHE | |
| SCHEMBL4823833 | 0.83 | CES2 (0.80) | CES1CES2CA1CA2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-1790640-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20050070591-A1 | Indole derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1464645-A1 | INDOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-10-06 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CBR1, NR0B1, CNKSR1 | CES1 944/4885CES2 2605/4885CA1 310/4885 |
| US-20050070591-A1 | Indole derivative | TPH1, IDO1, RBX1 | CES1 1805/4885CES2 3380/4885CA1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.